Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Atara Biotherapeutics's enterprise value was $67.82M on Nov 11, 2026, against $95.16M a year earlier. Over the last 5 years it ranged from -$57.85M to $1.03B, with a median of $31.20M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $67.82M | -41.9% |
| 2025 | Dec 31, 2025 | $116.72M | +1187.6% |
| 2024 | Dec 31, 2024 | $9.06M | – |
| 2023 | Dec 29, 2023 | -$50.29M | -213.1% |
| 2022 | Dec 30, 2022 | $44.45M | -95.7% |
| 2021 | Dec 31, 2021 | $1.03B | -12.9% |
| 2020 | Dec 31, 2020 | $1.19B | +95.6% |
| 2019 | Dec 31, 2019 | $607.12M | -50.2% |
| 2018 | Dec 31, 2018 | $1.22B | – |
| 2017 | Dec 29, 2017 | -$201.06M | -253.0% |
| 2016 | Dec 30, 2016 | $131.41M | -81.1% |
| 2015 | Dec 31, 2015 | $693.63M | +4624.5% |
| 2014 | Dec 31, 2014 | $14.68M | – |
See a number that looks wrong?